Blueprint Medicines Shares Jump on View That Ayvakit Could Hit $2B in Revenue by 2030

Dow Jones

Jan 14

By Owen Tucker-Smith

Shares of Blueprint Medicines rose after the company said its flagship drug Ayvakit could bring in $2 billion in revenue by 2030.

Shares were recently up 14%, to $99.70, midday Monday. The stock is up almost 15% since the start of the year.

The Cambridge, Mass., company on Sunday said in a 2025 outlook that Ayvakit could garner $2 billion in revenue by 2030. The drug treats Indolent Systemic Mastocytosis, which causes a buildup of abnormal mast cells in the body.

The company also shared results from its trial for BLU-808. Percy Carter, the company's chief scientific officer, said that the data from the trial indicated that the drug had "best-in-class potential."

In 2025, the company said it hopes to drive growth through revenue from Ayvakit and from the accelerated development of its BLU-808.

Blueprint expects Ayvakit to generate between $140 million and $145 million in sales for the fourth quarter, for a year-over-year growth rate of about 97%. The company expects to report fourth-quarter results in February.

CEO Kate Haviland was also scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday.

Write to Owen Tucker-Smith at owen.tucker-smith@wsj.com

(END) Dow Jones Newswires

January 13, 2025 14:34 ET (19:34 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2503532016"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503532016\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2503532016?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-14 03:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503532016","market":"nz","top_or_hot":-1,"title":"Blueprint Medicines Shares Jump on View That Ayvakit Could Hit $2B in Revenue by 2030","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Owen Tucker-Smith \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Blueprint Medicines rose after the company said its flagship drug Ayvakit could bring in $2 billion in revenue by 2030. \n</p>\n<p>\n  Shares were recently up 14%, to $99.70, midday Monday. The stock is up almost 15% since the start of the year. \n</p>\n<p>\n  The Cambridge, Mass., company on Sunday said in a 2025 outlook that Ayvakit could garner $2 billion in revenue by 2030. The drug treats Indolent Systemic Mastocytosis, which causes a buildup of abnormal mast cells in the body. \n</p>\n<p>\n  The company also shared results from its trial for BLU-808. Percy Carter, the company's chief scientific officer, said that the data from the trial indicated that the drug had \"best-in-class potential.\" \n</p>\n<p>\n  In 2025, the company said it hopes to drive growth through revenue from Ayvakit and from the accelerated development of its BLU-808. \n</p>\n<p>\n  Blueprint expects Ayvakit to generate between $140 million and $145 million in sales for the fourth quarter, for a year-over-year growth rate of about 97%. The company expects to report fourth-quarter results in February. \n</p>\n<p>\n  CEO Kate Haviland was also scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Owen Tucker-Smith at owen.tucker-smith@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 13, 2025 14:34 ET (19:34 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Blueprint Medicines Shares Jump on View That Ayvakit Could Hit $2B in Revenue by 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBlueprint Medicines Shares Jump on View That Ayvakit Could Hit $2B in Revenue by 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-14 03:34</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Owen Tucker-Smith \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Blueprint Medicines rose after the company said its flagship drug Ayvakit could bring in $2 billion in revenue by 2030. \n</p>\n<p>\n  Shares were recently up 14%, to $99.70, midday Monday. The stock is up almost 15% since the start of the year. \n</p>\n<p>\n  The Cambridge, Mass., company on Sunday said in a 2025 outlook that Ayvakit could garner $2 billion in revenue by 2030. The drug treats Indolent Systemic Mastocytosis, which causes a buildup of abnormal mast cells in the body. \n</p>\n<p>\n  The company also shared results from its trial for BLU-808. Percy Carter, the company's chief scientific officer, said that the data from the trial indicated that the drug had \"best-in-class potential.\" \n</p>\n<p>\n  In 2025, the company said it hopes to drive growth through revenue from Ayvakit and from the accelerated development of its BLU-808. \n</p>\n<p>\n  Blueprint expects Ayvakit to generate between $140 million and $145 million in sales for the fourth quarter, for a year-over-year growth rate of about 97%. The company expects to report fourth-quarter results in February. \n</p>\n<p>\n  CEO Kate Haviland was also scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Owen Tucker-Smith at owen.tucker-smith@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 13, 2025 14:34 ET (19:34 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BPMC","symbol_name":"Blueprint Medicines Corporation","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2503532016","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503532016","pubTimestamp":1736796840,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Blueprint Medicines rose after the company said its flagship drug Ayvakit could bring in $2 billion in revenue by 2030.Shares were recently up 14%, to $99.70, midday Monday. The stock is up almost 15% since the start of the year.The Cambridge, Mass., company on Sunday said in a 2025 outlook that Ayvakit could garner $2 billion in revenue by 2030. The drug treats Indolent Systemic Mastocytosis, which causes a buildup of abnormal mast cells in the body.The company also shared results from its trial for BLU-808. Percy Carter, the company's chief scientific officer, said that the data from the trial indicated that the drug had \"best-in-class potential.\". In 2025, the company said it hopes to drive growth through revenue from Ayvakit and from the accelerated development of its BLU-808.Blueprint expects Ayvakit to generate between $140 million and $145 million in sales for the fourth quarter, for a year-over-year growth rate of about 97%. The company expects to report fourth-quarte","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BPMC":"Blueprint Medicines Corporation"},"translate_title":"Blueprint Medicines股价因Ayvakit到2030年收入可能达到20亿美元而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BPMC":1},"content_text":"By Owen Tucker-Smith \n\n\n \n\n\n  Shares of Blueprint Medicines rose after the company said its flagship drug Ayvakit could bring in $2 billion in revenue by 2030. \n\n\n  Shares were recently up 14%, to $99.70, midday Monday. The stock is up almost 15% since the start of the year. \n\n\n  The Cambridge, Mass., company on Sunday said in a 2025 outlook that Ayvakit could garner $2 billion in revenue by 2030. The drug treats Indolent Systemic Mastocytosis, which causes a buildup of abnormal mast cells in the body. \n\n\n  The company also shared results from its trial for BLU-808. Percy Carter, the company's chief scientific officer, said that the data from the trial indicated that the drug had \"best-in-class potential.\" \n\n\n  In 2025, the company said it hopes to drive growth through revenue from Ayvakit and from the accelerated development of its BLU-808. \n\n\n  Blueprint expects Ayvakit to generate between $140 million and $145 million in sales for the fourth quarter, for a year-over-year growth rate of about 97%. The company expects to report fourth-quarter results in February. \n\n\n  CEO Kate Haviland was also scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday. \n\n\n \n\n\n  Write to Owen Tucker-Smith at owen.tucker-smith@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 13, 2025 14:34 ET (19:34 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}